MedTrace Logo

Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19

NCT04366791 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2022-03-29

No results posted yet for this study

Summary

This phase I/II trial studies low-dose radiation therapy as a focal anti-inflammatory treatment for patients with pneumonia or SARS associated with COVID-19 infection.

Conditions

  • Pneumonia
  • Coronavirus Infection in 2019 (COVID-19)
  • Severe Acute Respiratory Syndrome (SARS) Pneumonia

Interventions

RADIATION

Low Dose Radiation Therapy

Undergo low-dose radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Mohammad Khan, MD, PhD · Emory University Hospital/Winship Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-24
Primary Completion
2022-03-11
Completion
2022-03-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04366791 on ClinicalTrials.gov